Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination–proficient ovarian cancer is a research paper published in Journal of Clinical Investigation (2025). On theSindex it has a DataRank of 0. It has been cited 7 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Duke University School of Medicine
Grant: -
Alvin J. Siteman Cancer Center
Grant: 5T32CA113275-17
Molecular Oncology Training Grant
Foundation for Barnes-Jewish Hospital
Grant: CTRFP1719
Veterans Affair
Grant: VA-ORD I01BX006020
NIH
Grant: R01CA243511
BLRD VA
Grant: I01 BX006020
NCATS NIH HHS
Grant: R03 TR004017
NCI NIH HHS
Grant: K12 CA090628
NCI NIH HHS
Grant: P50 CA244431
NCI NIH HHS
Grant: T32 CA113275
National Institutes of Health
Grant: 5P50CA244431-02
Washington University Implementation Science Center for Cancer Control
National Institutes of Health
Grant: 1R03TR004017-01A1
Evaluating the impact of Basic needs Assessment and Support to Improve Colposcopy Show rate: The BASICS Trial
National Institutes of Health
Grant: 3R01CA243511-04S1
Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer - Diversity Supplement
National Institutes of Health
Grant: 5I01BX006020-02
BCCMA: Overcoming chemoresistance in ovarian cancer: Identification and validation of biomarkers and targetable drivers of platinum resistance
FWCI
7.54
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals